Pfizer is moving forward with its hopes for a monthly obesity drug. A newly acquired weight loss drug has shown promise as a monthly treatment. Pfizer recently bought biotech firm Metsera for $4.9 billion, gaining access to its portfolio of anti-obesity and cardiometabolic disease therapies. Metsera has four programs in clinical testing and one in mid-stage. Pfizer does not yet have an anti-obesity drug on the market, but it has several projects in development. This year, he ended development of a potential daily pill ahead of phase three clinical trials. The market for obesity drugs has become increasingly competitive due to the success of products such as Wegovy and Zepbound.[4][5][7][9]